Intrinsiqq
Mineralys Therapeutics, Inc. logo

Mineralys Therapeutics, Inc. Insider Trading

MLYS

Compare
Last 12 months

Insiders bought $8.76M and sold $27.9M on the open market.

89% of the selling was scheduled in advance under 10b5-1 plans. Director Brian Taylor Slingsby sold $3.01M on Sep 22 outside a plan.

Net open-market
−$19.2M
1 buy · 36 sales
Under a 10b5-1 plan
89%
of the value sold
Insiders who bought / sold
1 / 6
executives and directors
Last open-market buy
Mar 2026
Mar 30, 2026

Get an email when MLYS's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

  • Sep 3010b5-1 plan
    Jon Congleton
    Chief Executive Officer · sold 75,000 at $25.46
    $1.91M
    12% of stake
  • Sep 22No plan
    Brian Taylor Slingsby
    Director · sold 104,320 at $28.81
    $3.01M
    1.3% of stake
  • Sep 2110b5-1 plan
    Eric Warren
    Chief Commercial Officer · sold 7,438 at $28.12
    209K
    16% of stake
  • Sep 1510b5-1 plan
    Daphne Karydas
    Director · sold 3,000 at $28.58
    86K
    33% of stake
  • Aug 2110b5-1 plan
    Eric Warren
    Chief Commercial Officer · sold 7,437 at $25.98
    193K
    16% of stake
  • Aug 1010b5-1 plan
    David Malcom Rodman
    Chief Medical Officer · sold 2,170 at $27.09
    59K
    4.1% of stake
  • Jul 2110b5-1 plan
    Eric Warren
    Chief Commercial Officer · sold 7,438 at $26.87
    200K
    16% of stake
  • Jul 1710b5-1 plan
    David Malcom Rodman
    Chief Medical Officer · sold 416 at $26.53
    11K
    0.8% of stake
  • Jul 13 – 1510b5-1 plan
    David Malcom Rodman
    Chief Medical Officer · sold 20,407 at avg $27.28
    557K
    28% of stake
  • Jul 1310b5-1 plan
    Jon Congleton
    Chief Executive Officer · sold 10,700 at $27.24
    291K
    1.7% of stake
  • Jul 910b5-1 plan
    David Malcom Rodman
    Chief Medical Officer · sold 2,171 at $30.30
    66K
    3.6% of stake
  • Jun 3010b5-1 plan
    Jon Congleton
    Chief Executive Officer · sold 75,000 at avg $26.14
    $1.96M
    11% of stake
  • Jun 2610b5-1 plan
    Eric Warren
    Chief Commercial Officer · sold 104,124 at $25.90
    $2.7M
    73% of stake
  • Jun 15 – 1710b5-1 plan
    David Malcom Rodman
    Chief Medical Officer · sold 14,474 at avg $24.19
    350K
    20% of stake
  • Jun 1710b5-1 plan
    Daphne Karydas
    Director · sold 3,000 at $25.00
    75K
    33% of stake
  • Jun 10 – 1210b5-1 plan
    David Malcom Rodman
    Chief Medical Officer · sold 8,519 at avg $24.20
    206K
    12% of stake
  • May 1810b5-1 plan
    David Malcom Rodman
    Chief Medical Officer · sold 417 at $27.55
    11K
    0.7% of stake
  • May 11 – 1310b5-1 plan
    David Malcom Rodman
    Chief Medical Officer · sold 22,575 at avg $28.91
    653K
    26% of stake
  • Apr 1710b5-1 plan
    David Malcom Rodman
    Chief Medical Officer · sold 416 at $31.33
    13K
    0.6% of stake
  • Apr 13 – 1510b5-1 plan
    David Malcom Rodman
    Chief Medical Officer · sold 20,406 at avg $26.89
    549K
    23% of stake
  • Apr 1310b5-1 plan
    Jon Congleton
    Chief Executive Officer · sold 15,730 at $26.83
    422K
    2.2% of stake
  • Apr 910b5-1 plan
    David Malcom Rodman
    Chief Medical Officer · sold 2,170 at $27.38
    59K
    2.8% of stake
  • Mar 3110b5-1 plan
    Daphne Karydas
    Director · sold 3,000 at $25.00
    75K
    33% of stake
  • Mar 3110b5-1 plan
    Jon Congleton
    Chief Executive Officer · sold 75,000 at avg $26.27
    $1.97M
    9.6% of stake
  • Mar 27 – 30
    Rajeev M. Shah
    Director · bought 369,000 at avg $23.75
    $8.76M
    6.8% of stake
  • Mar 1710b5-1 plan
    David Malcom Rodman
    Chief Medical Officer · sold 417 at $25.65
    11K
    0.5% of stake
  • Mar 12 – 1310b5-1 plan
    David Malcom Rodman
    Chief Medical Officer · sold 20,406 at avg $26.61
    543K
    21% of stake
  • Mar 910b5-1 plan
    David Malcom Rodman
    Chief Medical Officer · sold 2,171 at $26.84
    58K
    2.6% of stake
  • Feb 1710b5-1 plan
    David Malcom Rodman
    Chief Medical Officer · sold 417 at $27.59
    12K
    0.9% of stake
  • Feb 12 – 1310b5-1 plan
    David Malcom Rodman
    Chief Medical Officer · sold 20,404 at avg $27.93
    570K
    32% of stake
  • Feb 910b5-1 plan
    David Malcom Rodman
    Chief Medical Officer · sold 2,171 at $30.21
    66K
    4.1% of stake
  • Jan 2010b5-1 plan
    David Malcom Rodman
    Chief Medical Officer · sold 416 at $32.10
    13K
    0.8% of stake
  • Jan 13 – 1410b5-1 plan
    David Malcom Rodman
    Chief Medical Officer · sold 19,076 at avg $32.67
    623K
    27% of stake
  • Jan 1210b5-1 plan
    Adam Scott Levy
    CFO and Secretary · sold 10,758 at $32.14
    346K
    55% of stake
  • Jan 9 – 1210b5-1 plan
    David Malcom Rodman
    Chief Medical Officer · sold 8,518 at avg $32.56
    277K
    12% of stake
  • Jan 1210b5-1 plan
    Jon Congleton
    Chief Executive Officer · sold 16,236 at avg $32.62
    530K
    2.5% of stake
  • Jan 2 – 510b5-1 plan
    David Malcom Rodman
    Chief Medical Officer · sold 262,752 at avg $35.25
    $9.26M
    81% of stake
  • Nov 20, 2025No plan
    Catalys Pacific Fund, LP
    Large holder · sold 1,000,000 at $43.35
    $43.4M
    11% of stake
  • Nov 13, 2025No plan
    Daphne Karydas
    Director · sold 15,000 at avg $45.99
    690K
    100% of stake
  • Nov 11, 2025 – Nov 13, 2025No plan
    Alexander M Gold
    Director · sold 34,675 at avg $45.45
    $1.58M
    100% of stake
How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch MLYS, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with MLYS

CompareIntrinsic value
INVAInnoviva Inc.
$18.41+0.00%60
PAHCPhibro Animal Health Corporation
$33.29-2.32%57
NUVBNuvation Bio Inc.
$3.80-0.26%10
RAREUltragenyx Pharmaceutical Inc.
$16.48-4.30%40
PRGOPerrigo Company plc
$15.94-0.62%17
RCUSArcus Biosciences Inc.
$15.62-1.01%10
XNCRXencor Inc.
$33.26-2.21%11
VRDNViridian Therapeutics Inc.
$29.93-4.80%40

Held by ETFs

MLYS is in 37 US ETFs. The largest of them, with MLYS's weight in each:

Spot a number that looks wrong? Check it in MLYS's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing MLYS

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.